Insulet Corporation · NASDAQ:PODD
Insulet — J.P. Morgan 43rd Annual Healthcare Conference 2025
21 slides from Insulet's conference presentation, Jan 14, 2025
Slide 1: J.P. Morgan 43rd Healthcare Conference
J.P. Morgan 43 Healthcare rd Conference Chloe The Pod has an IP28 rating for up to 25 feet for 60 minutes. The PDM and Controller are not waterproof.
Slide 2: Forward Looking Statement and Non-GAAP Financial Measures
Forward Looking Statement This presentation may contain forward-looking statements concerning Insulet's expectations, anticipations, intentions, beliefs or strategies regarding the future. These forward-looking statements are based on current expectations and beliefs concerning future developments a
Slide 3: Insulet at a Glance
1 Insulet at a Glance Dan Podder since 2019 3
Slide 4: Our mission is to improve the lives of people with diabetes
Our mission is to improve the lives of people with diabetes and enable our customers to enjoy simplicity, freedom, and healthier lives through innovative technology. 4
Slide 5: The Global Leader in Diabetes Management
The Global Leader in Diabetes Management The first and only AID #1 in U.S. new customer starts1 system cleared for both #1 prescribed AID in the U.S. in 20231 type 1 and type 2 in the U.S. #1 insulin pump for new pump users in Europe1 ~$2B 425K+ 250K+ 25 2024 Revenue2 Active Customers3 Using Omnipod
Slide 6: Omnipod 5 Addresses the Unmet Needs of People Living with Type 1 and Type 2 Diabetes
Omnipod 5 Addresses the Unmet Needs of People Living with Type 1 and Type 21 Diabetes First tubeless, waterproof2 AID in the U.S. World-class algorithm built into the Pod Choice of sensor integration3 Phone control with Android or iOS4 Pod show n without nece ssary adhesive. 1. The expanded indicati
Slide 7: Omnipod 5 Type 2 Indication Unlocks Significant New Growth Opportunity
Omnipod 5 Type 2 Indication Unlocks Significant New Growth Opportunity U.S. FDA Clearance for adults with Strong SECURE-T2D clinical results: type 2 diabetes received August 2024 Commercialization Plans: Baseline 8.2 • Expand relationships and -0.8% 1 deepen call points with Endos and high-prescribi
Slide 8: Scale and Significant Competitive Moats Support Sustainable, Profitable Growth
Scale and Significant Competitive Moats Support Sustainable, Profitable Growth Unique Patch Widespread, Optimized Advanced Data Pump Form Factor Affordable Access Manufacturing Capabilities Tubeless, discreet, Available in 44,000 20+ years of Cloud connectivity wearable AID protected U.S. pharmacies
Slide 9: Strong Fundamentals Powering Financial Results
Strong Fundamentals Powering Financial Results Growing Leading Rapidly Expanding Revenue to $2B Gross Margin Operating Margin 23% +390 bps +770 bps CAGR Expansion Expansion ~$2.0 ~69% ~14.5% 6.8% $0.7 65.1% 2019 2024E 1 2019 2024E 1 2019 2024E 1 1. Reflects midpoint of full year 2024 revenue guidanc
Slide 10: Executing on a Large Market Opportunity
Executing on a Large 2 Market Opportunity David Podder since 2020 10
Slide 11: A Massive Global Market Opportunity with Substantial Runway for Growth
A Massive Global Market Opportunity with Substantial Runway for Growth Targeting Large, Underpenetrated, and Expanding Insulin-Intensive Markets ~3.5M 3.0M+ ~3.5M ~14M ~2.5M Total Addressable ~1.7M Market1 of Patients We are positioned to improve the lives of ~40% ~20% millions of people with ~5% di
Slide 12: Clear Strategy to Drive Continued Growth and Market Leadership
Clear Strategy to Drive Continued Growth and Market Leadership Advance Lead Drive Omnipod 5 platform with ongoing growth in U.S. access to Omnipod 5 cascade of innovation, type 1 and type 2 in international fueled by data markets markets 12
Slide 13: Advance Omnipod 5 Platform with Cascade of Innovation, Fueled by Data
Advance Omnipod 5 Platform with Cascade of Innovation, Fueled by Data Product Vision At launch Today (FMR August 2022) Omnipod of the Future Tubeless wearable disposable form factor Continuous focus on Sensor integration G6 G6 G7 FSL2+ product enhancement Markets U.S. U.S. & International Seamless i
Slide 14: Lead Ongoing Growth in U.S. Type 1 and Type 2 Markets
Lead Ongoing Growth in U.S. Type 1 and Type 2 Markets ~29% • Extend lead in type 1 CAGR1 ~$1.5B • Drive type 2 adoption through awareness of SECURE-T2D clinical data • Build customer base to further strengthen recurring, annuity model $420M • Invest in commercial excellence and a world-class custome
Slide 15: Drive Access to Omnipod 5 in International Markets
Drive Access to Omnipod 5 in International Markets • Leverage proven playbook as we expand internationally ~15% • Utilize clinical evidence to expand prescribers and access CAGR1 • Accelerate pace of Omnipod 5 market launches ~$517M 2023 2024 U.K. Germany France Netherlands 2025 Launched January $25
Slide 16: Well-Positioned for Sustainable, Profitable Growth
Expanding game-changing Omnipod 5 platform; first and only AID cleared for type 2 diabetes Well- Extending market leadership and competitive Positioned for moats through cascade of innovation Sustainable, Leading growth in U.S. type 1 and type 2 markets Profitable Driving adoption of Omnipod 5 in 10
Slide 17: Driven by Our Commitment to Improve the Lives of People with Diabetes
Driven by Our Commitment to Improve the Lives of People with Diabetes “ I spent 15+ years on MDI. I didn’t know how easy nighttime could be until now. After only three months, I have a better A1c, fewer lows and a big improvement in time in range. “ Omnipod 5 has been remarkable. Milli Podder since
Slide 18: Thank You
Thank You Insulet
Slide 19: Insulet Common Abbreviations and Acronyms
Insulet Common Abbreviations and Acronyms A1c Blood test measures average blood glucose levels over the last 3 months GAAP Generally Accepted Accounting Principles AID Automated Insulin Delivery HCP Health Care Provider bps Basis Points iOS iPhone Operating System CAGR Compounded Annual Growth Rate
Slide 20: 2024 Guidance Provided On Q3'24 Earnings Call
2024 Guidance Provided On Q3'24 Earnings Call1 Revenue Guidance2 Margin Guidance Assumptions & Drivers Q4'24 FY 2024 FY 2024 FY 2024 Continued strong Omnipod 5 Revenue Revenue Raise Gross Margin Operating Margin Raise adoption globally 12% to 15% 20% to 21% ~69% ~14.5% U.S. & Int'l NCS growth YoY an
Slide 21: Non-GAAP Reconciliation — Revenue Guidance
Non-GAAP Reconciliation — Revenue Guidance Year Ending December 31, 2024 Revenue Growth GAAP Currency Impact Constant Currency U.S. Omnipod 19% to 21% —% 19% to 21% International Omnipod 26% to 28% 1% 25% to 27% Total Omnipod 21% to 22% —% 21% to 22% Drug Delivery (10)% to (5)% —% (10)% to (5)% Tota
Insulet — J.P. Morgan 43rd Annual Healthcare Conference 2025 on 6ix